• Reckitt management spoke at a Barclays conference in Boston in FY26, joined by Barclays analyst Warren Ackerman.
• CEO Kris Licht highlighted a unanimous win in the US MDL litigation, with the next trial date flagged for Nov. 27.
• Licht signaled pragmatism on an eventual resolution, while stressing recent wins across jurisdictions do not end the process.
• Mead Johnson described as a strong cash-generative asset drawing inbound interest; no sale process running, though all strategic options remain open.
• CFO Shannon Eisenhardt said emerging-market price rises have landed since April/May; US-Europe increases expected to reach shelves in September/October.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Reckitt Benckiser Group plc published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.